| U. Martin Fuhs |
U. Martin Fuhs currently works at Alpine Immune Sciences, Inc., as Chief Accounting Officer & Vice President-Finance from 2024. Mr. Fuhs received his graduate degree from the University of Bonn. |
| Christina Yi |
Christina Yi is currently the Chief Technology Officer at Alpine Immune Sciences, Inc. She previously worked as the Chief Operating Officer at Provention Bio, Inc. and Dendreon Pharmaceuticals LLC. From 2020 to 2021, she was the Chief Operating Officer at Vaxxinity, Inc. Ms. Yi received her undergraduate degree from the University of Washington. |
| Remy Durand |
Remy Durand is currently working as a Principal at Alpine Bioventures, GP, LLC since 2018. Additionally, Dr. Durand holds the position of Chief Business Officer at Alpine Immune Sciences, Inc. since 2021. Previously, Dr. Durand worked as a Vice President at Frazier Management LLC from 2015 to 2018. Dr. Durand also held a position as a Principal at GE Ventures LLC. Furthermore, Dr. Durand worked as a Senior Life Sciences Specialist at L.E.K. Consulting LLC from 2011 to 2013. Dr. Durand holds a doctorate degree from Stanford University and an undergraduate degree from Case Western Reserve University. |
| Wolfgang Dummer |
Wolfgang Dummer is a professional with a doctorate degree from Technische Universität München. He is currently the Chief Medical Officer at Alpine Immune Sciences, Inc. He previously served as the Chief Medical Officer & Executive Vice President at Rigel Pharmaceuticals, Inc. from 2019 to 2023. Prior to that, he was the Chief Medical Officer at Aridis Pharmaceuticals, Inc. from 2018 to 2019. From 2012 to 2016, he worked as the Vice President-Clinical Development at BioMarin Pharmaceutical, Inc. |
| James Paul Rickey |
James Paul Rickey's current job(s) include being the Director at The Association of Bioscience Financial Officers and the CFO, Secretary, Treasurer & Senior Vice President at Alpine Immune Sciences, Inc. Mr. Rickey's former job(s) include being a Principal at Ernst & Young LLP, a Controller at Northstar Neuroscience, Inc., the Chief Financial Officer & Vice President at Sound Pharmaceuticals, Inc., an Accounting Manager at Mobliss, Inc., and the Secretary, Treasurer, VP-Finance & Administration at Immune Design Corp. Mr. Rickey's education history includes completing undergraduate and graduate degrees at the University of Washington. |
| Mitchell H. Gold |
Mitchell H. Gold is the founder of Alpine Biosciences, Inc. (founded in 2012) and Elixis, Inc. (founded in 1995). He held the title of Chairman at Alpine Biosciences, Inc. from 2012 to 2014 and President & Chief Executive Officer at Elixis, Inc. from 1995 to 2000. Dr. Gold is also the founder of Alpine Bioventures, GP, LLC. Dr. Gold's current job(s) include being the Executive Chairman & Chief Executive Officer at Alpine Immune Sciences, Inc. since 2017. He is also a Director at Prostate Cancer Institute, Washington Biotechnology & Biomedical Association, the University of Washington, and a Member-Governors Board at Biotechnology Innovation Organization. Dr. Gold's former job(s) include being the Executive Chairman & Chief Executive Officer at Alpine Immune Sciences, Inc. He was also a Director at Dendreon Corp. from 2001 to 2013, SillaJen Biotherapeutics, Inc., and Fred Hutchinson Cancer Research Center. Additionally, he held the position of VP-Business Development, Sales & Marketing at Data Critical Corp. from 2000 to 2001. Dr. Gold's education history includes an undergraduate degree from the University of Wisconsin and a graduate degree from Rush Medical College. |
| Stanford L. Peng |
Stanford L. Peng is the President & Head-Research & Development at Alpine Immune Sciences, Inc. He previously worked as the Executive Director-Medical at Seagen Inc. from 2014 to 2015, Senior Director at ARYx Therapeutics, Inc. from 2008 to 2009, Chief Medical Officer & Head-Clinical Development at Stemcentrx, Inc. from 2015 to 2016, and Head-Rheumatology Clinical Research Unit at Benaroya Research Institute at Virginia Mason from 2009 to 2014. He also served as an Assistant Professor at Washington University School of Medicine from 2002 to 2005. Dr. Peng completed his undergraduate degree at Stanford University and holds a doctorate from Yale University. He also obtained graduate and doctorate degrees from Yale School of Medicine. |
| Robert E. Conway |
Robert E. Conway is currently the Chairman at ARCA biopharma, Inc., the Chairman at Wall Family Enterprise, Inc., the Executive Chairman at ClinOne, Inc., a Director at Biotechnology Innovation Organization, an Independent Director at Alpine Immune Sciences, Inc., a Director at Signant Health, a Director at Buccaneer Holdco Ltd., a Director at eResearch Technology, Inc., and a SAB Healthcare at Genstar Capital Management LLC. He previously served as the Chief Executive Officer & Director at Array BioPharma, Inc., a Director at PRA Health Sciences, Inc., a Director at ERT Operating Co., a Director at Bracket, Inc., a Director at Advarra, Inc., a Director at PRA International LLC, an Independent Director at Nivalis Therapeutics, Inc., the Vice President & General Manager at Corning, Inc., the Chief Operating Officer & Executive Vice President at Hill Top Research, Inc., the Vice President at Corning International Corp., and the Vice President & General Manager at Corning-Hazleton, Inc. He holds an undergraduate degree from Marquette University and an MBA from the University of Cincinnati (Ohio). |
| James N. Topper |
Jamie is a Managing Partner of Frazier Healthcare Partners' Life Sciences team. He joined Frazier in 2003 and opened Frazier's Menlo Park office in the same year. Throughout his 16 years as a Managing Partner, Jamie has invested across over 35 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.
Jamie has led many of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Amunix Pharmaceuticals (sold to Sanofi), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Ainara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Alpine Immune Sciences (NASDAQ: ALPN), AnaptysBio (NASDAQ: ANAB), Lassen Therapeutics, NewAmsterdam Pharma (NASDAQ: NAMS), Phathom Pharmaceuticals (NASDAQ: PHAT), and Seraxis. In addition, Jamie is a board observer for Alcresta Therapeutics. He previously served as Chairman and Chief Executive Officer of Frazier- sponsored SPAC Frazier Lifesciences Acquisition Corporation.
Prior to joining Frazier, Jamie was the head of cardiovascular R&D at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the medical school faculties at Stanford and Harvard Medical School prior to joining COR.
Jamie received his M.D. and Ph.D. in Biophysics from Stanford and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford. |
| Peter A. Thompson |
Peter A. Thompson founded Emergent Product Development Seattle in 1999, where he worked as Chairman, President & Chief Executive Officer from 2002 to 2009, Strategicon Partners in 2001, where he worked as Managing Director from 2001 to 2013, Cleave Therapeutics, Inc. in 2010, where he is working as Director from 2010, and various other companies. Dr. Thompson also founded Newyu, Inc., where he worked as Chairman & Chief Executive Officer and Terremoto Biosciences, Inc., where he is working as Chief Executive Officer & Director. Dr. Thompson also currently works at Cardioxyl Pharmaceuticals LLC, as Director, OxOnc Development LP, as Director, ReCode Therapeutics, Inc., as Director, and various other companies. Dr. Thompson also formerly worked at Response Biomedical Corp., as Executive Chairman from 2012 to 2014, Sierra Oncology, Inc., as Independent Director from 2014 to 2015, Anthera Pharmaceuticals, Inc., as Independent Director from 2011 to 2013, and various other companies. Dr. Thompson received his undergraduate degree in 1981 from Brown University and doctorate degree in 1984 from The Warren Alpert Medical School. |
| Xiang Ming Cui |
Xiang Ming Cui was the founder of Pan Pacific Pharmaceuticals, Inc. where he served as the Chief Scientific Officer & Executive VP from 1998 to 2002. He is also the founder of CNetwork and Decheng Capital LLC. Dr. Cui's current jobs include being a Director at Cardiomedics, Inc., Sinomed, Inc., Shenzhen GeneMDx Biotech Co., Ltd., AccuraGen, Inc., GRAIL LLC, Alpine Immune Sciences, Inc., Mammoth Biosciences, Inc., Nanjing Bioheng Biotech Co., Ltd., Levitasbio, Inc., Ariagen, Inc., Immpact Bio USA, Inc., Ketai Medical Device Ltd., and Nuvation Bio, Inc. Dr. Cui's former jobs include being a Managing Director at GeneWeave Biosciences, Inc., a Director at GenapSys, Inc., a Director-Strategic Investment Planning at Southern Research Institute, a Director at China Biologic Products, Inc., a Director at GENTURAdx USA, Inc., a Director at ARMO BioSciences, Inc., a Director at Cue Health, Inc., a Director at EpimAb Biotherapeutics, Inc., a Director at Levitas, Inc., a Director at Hummingbird Bioscience Pte Ltd., a Director at VelosBio, Inc., a Director at Shanghai Ketai Medical Device Co., Ltd., and a Principal at Bay City Capital LLC. Dr. Cui's education includes a doctorate degree from Stanford University and undergraduate and graduate degrees from Peking University. Dr. Cui is also the founder of CNetwork, Decheng Capital LLC. |
| Christopher Peetz |
Christopher Peetz is the founder of Mirum Pharmaceuticals, Inc. (founded in 2018) where he holds the title of Chief Executive Officer & Director. He is currently the Chief Executive Officer at Satiogen Pharmaceuticals, Inc. and an Independent Director at Alpine Immune Sciences, Inc. Mr. Peetz's former positions include being the Chief Executive Officer at Flashlight Therapeutics, Inc. from 2014 to 2016, Senior Director-Corporate Development & Strategy at Onyx Pharmaceuticals, Inc. from 2007 to 2012, and Vice President-Finance & Development at SillaJen Biotherapeutics, Inc. from 2012 to 2014. He also held the position of Chief Financial Officer & Head-Development at Tobira Therapeutics, Inc. from 2014 to 2016. Mr. Peetz received his undergraduate degree from Washington University in St. Louis and an MBA from Stanford Graduate School of Business. |
| Natasha A. Hernday |
Natasha A. Hernday is an Independent Director at XOMA Corp. and Alpine Immune Sciences, Inc. She is also the Chief Business Officer at Seagen Inc. Previously, she worked as the Director-Mergers, Acquisitions & Out-Partnering at Amgen, Inc. from 1994 to 2010 and as an Independent Director at PDL BioPharma, Inc. from 2019 to 2022. Ms. Hernday holds an MBA from Pepperdine University and an undergraduate degree from the University of California, Santa Barbara. |
